22 May 2013
Keywords: editor, views, astazeneca, exanta, woes, bayer/s-p, deal
Article | 20 September 2004
It seems strange that AstraZeneca's new anticoagulant Exanta(ximelagatran) is safe and effective for European patients but not for
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
20 September 2004
13 September 2004
21 May 2013
© 2013 thepharmaletter.com